Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10661125 | 0.89 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL23928219 | 0.88 | HRH3 (0.77) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| Hydrochloric Acid SCHEMBL30876469 | 0.87 | HRH3 (0.74) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL10662153 | 0.87 | HRH3 (0.77) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL873480 | 0.84 | CYP1A2 (0.57) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL28595265 | 0.84 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL19026551 | 0.83 | HRH3 (0.77) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL874146 | 0.83 | HRH3 (0.74) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL16804688 | 0.83 | KCNH2 (0.59) | LTA4HKCNH2 | |
| SCHEMBL16804694 | 0.83 | KCNH2 (0.63) | HRH3LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619184-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | The Regents of the University of Michigan (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040527-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | WO | disclosed |
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7820678-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1599096-B1 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080076782-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7345044-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-7030117-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-7026325-B2 | Sodium channel blockers | PARION-SCIENCES, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060063780-A1 | Sodium channel blockers | JOHNSON MICHAEL R | 2006-03-23 | — | — | US | disclosed |
| EP-1599096-A4 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6995160-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1599096-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6903105-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050113389-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113388-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113390-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2004073629-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162296-A1 | Sodium channel blockers | PARION SCIENCES, INC. | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | HRH3 963/4885KEAP1 3183/4885NFE2L2 2469/4885 |
| US-20050113390-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | HRH3 1516/4885KEAP1 1076/4885NFE2L2 3712/4885 |
| US-20050113389-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | HRH3 1516/4885KEAP1 1076/4885NFE2L2 3712/4885 |
| US-20080076782-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | HRH3 1516/4885KEAP1 1076/4885NFE2L2 3712/4885 |
| US-20050113388-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | HRH3 1516/4885KEAP1 1076/4885NFE2L2 3712/4885 |
| US-20040162296-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | HRH3 1516/4885KEAP1 1076/4885NFE2L2 3712/4885 |
| US-20060063780-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | HRH3 1516/4885KEAP1 1076/4885NFE2L2 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.